Research Article
Simultaneous Gemcitabine and Percutaneous CT-Guided Irreversible Electroporation for Locally Advanced Pancreatic Cancer
Table 3
Univariate and multivariate analyses of local tumor progression free survival.
| | Characteristic | Univariate analysis | Multivariate analysis | | HR (95% CI) | value | HR (95% CI) | value |
| | Age | ≤60/>60 | 0.654 (0.565–1.818) | 0.185 | | | | Sex | Female/male | 1.588 (0.927–2.579) | 0.056 | | | | Tumor site | Head/body/tail | 1.167 (0.6987–1.640) | 0.960 | | | | Tumor size (cm) | ≤5/>5 | 1.154 (0.776–1.705) | 0.512 | | | | Tumor volume (cm3) | ≤37/>37 | 2.356 (1.367–3.161) | 0.001 | 1.683 (1.035–3.191) | 0.032 | | Local recurrence | ≤6 mo/>6 mo | 0.445 (0.245–0.975) | 0.024 | 0.526 (0.225–1.325) | 0.151 | | WBC (×109) | ≤10/>10 | 1.154 (0.479–2.658) | 0.811 | | | | HGB (g/L) | ≤120/>120 | 0.673 (0.318–1.535) | 0.369 | | | | PLT (×109) | ≤300/>300 | 0.623 (0.256–1.338) | 0.206 | | | | ALT (U/L) | ≤40/>40 | 0.741 (0.325–1.437) | 0.356 | | | | AST (U/L) | ≤40/>40 | 0.678 (0.328–1.478) | 0.246 | | | | ALP (U/L) | ≤100/>100 | 0.823 (0.446–1.489) | 0.744 | | | | CA19-9 level | ≤35/>35 | 2.156 (1.034–4.265) | 0.045 | 1.916 (0.931–3.568) | 0.078 | | Complications | Yes/no | 0.645 (0.334–1.451) | 0.095 | | | | IRE | With/without GEM | 0.545 (0.326–1.051) | 0.047 | 0.556 (0.315–1.260) | 0.043 |
|
|
IRE: irreversible electroporation; GEM: gemcitabine; HR: hazard ratio; WBC: white blood cell count; HGB: hemoglobin; PLT: platelet count; ALT: alanine transaminase; AST: aspartate aminotransferase; ALP: alkaline phosphatase; CA19-9: carbohydrate antigen 19-9.
|
